INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Adamas Pharmaceuticals, Inc. Investors

Law Offices of Howard G. Smith announces an investigation on behalf of Adamas Pharmaceuticals, Inc. ("Adamas" or the "Company") ADMS investors concerning the Company and its officers' possible violations of federal securities laws.

On March 4, 2019, Adamas revised previous prescription growth estimates for GOCOVRI, the Company's primary product, warned of a continued slowdown in GOCOVRI prescriptions, and refused to predict GOCOVRI's ability to achieve a sizeable market share.

On this news, Adamas' share price fell $3.99 per share, or more than 32%, to close at $8.16 per share on March 5, 2019, thereby injuring investors.

Then, on September 30, 2019, an analyst lowered its rating on Adamas due to "existing overhangs," including lack of "Gocovri coverage: a number of national formularies exclude Gocovri." The analyst "expect[ed] reimbursement hurdles in MSWI space especially with generic Ampyra launch."

On this news, Adamas' share price fell $3.02 per share, or more than 42%, over several trading sessions to close at $4.03 per share on October 3, 2019, thereby injuring investors further.

If you purchased Adamas securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191212005874/en/